Diamed Obesity S.R.L.

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Chronic kidney disease2 trials
• Obesity2 trials
• Type 1 diabetes2 trials
• Heart failure1 trial
• High blood pressure1 trial

Phase

• Phase 38 trials

Status

• Completed4 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Novo Nordisk A/S3 trials
• Boehringer Ingelheim1 trial
• Regeneron Pharmaceuticals1 trial

Running trials

• Not yet recruiting

  Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.

  NCT05636176· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

  NCT05803421· Phase 3· Eli Lilly and Company· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source